• 1
    Dennert G, Zwahlen MMB, Vinveti M, Zeegers M, Horneber M. Selenium for preventing cancer. Cochrane Database of Systematic Reviews 2011.
  • 2
    Clark LC, Combs GFJ, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JLJ, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276: 195763.
  • 3
    Liu JZ, Gilbert K, Parker HM, Haschek WM, Milner JA. Inhibition of 7,12-dimethylbenz(a)anthracene-induced mammary tumors and DNA adducts by dietary selenite. Cancer Res 1991; 51: 46137.
  • 4
    Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 93540.
  • 5
    Feng Y, Finley JW, Davis CD, Becker WK, Fretland AJ, Hein DW. Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2′-dimethyl-4-aminobiphenyl. Toxicol Appl Pharmacol 1999; 157: 3642.
  • 6
    Suzuki KT, Kurasaki K, Ogawa S, Suzuki N. Metabolic transformation of methylseleninic acid through key selenium intermediate selenide. Toxicol Appl Pharmacol 2006; 215: 18997.
  • 7
    Ip C, Ganther HE. Activity of methylated forms of selenium in cancer prevention. Cancer Res 1990; 50: 120611.
  • 8
    Ip C, Hayes C, Budnick RM, Ganther HE. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991; 51: 595600.
  • 9
    Ganther HE. Pathways of selenium metabolism including respiratory excretory products. Int J Toxicol 1986; 5: 15.
  • 10
    Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF, Jr, Lu J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008; 29: 100512.
  • 11
    Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60: 28826.
  • 12
    Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, Lu J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Philadelphia, PA) 2009; 2: 48495.
  • 13
    Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent partial remission of breast cancer in ‘high risk’ patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Mol Aspects Med 1994; 15: S231S40.
  • 14
    Yan L, Yee JA, McGuire MH, Graef GL. Effect of dietary supplementation of selenite on pulmonary metastasis of melanoma cells in mice. Nutr Cancer 1997; 28: 1659.
  • 15
    Yan L, Yee JA, Li D, McGuire MH, Graef G. Dietary supplementation of selenomethionine reduces metastasis of melanoma cells in mice. Anticancer Res 1999; 19: 133742.
  • 16
    Institute of laboratory Animal Research. Guide for the care and use of laboratory Animals. Washington, D.C.: National Academy Press, 1996.
  • 17
    Reeves PG, Nielsen FH, Fahey GCJ. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993; 123: 193951.
  • 18
    Welch DR, Neri A, Nicolson GL. Comparison of ‘spontaneous’ and ‘experimental’ metastasis using rat 13726 mammary adenocarcinoma metastatic cell clones. Invasion Metastasis 1983; 3: 6580.
  • 19
    Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995; 376: 26979.
  • 20
    Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 2005; 11: 125166.
  • 21
    Yoon SO, Kim MM, Chung AS. Inhibitory effect of selenite on invasion of HT1080 tumor cells. J Biol Chem 2001; 276: 2008592.
  • 22
    Czekay RP, Loskutoff DJ. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 2004; 229: 10906.
  • 23
    Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 5313.
  • 24
    Gavrilov D, Kenzior O, Evans M, Calaluce R, Folk WR. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer 2001; 37: 103340.
  • 25
    Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82: 18493.
  • 26
    Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 9238.
  • 27
    Elokdah H, Abou-Gharbia M, Hennan JK, McFarlane G, Mugford CP, Krishnamurthy G, Crandall DL. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem 2004; 47: 34914.
  • 28
    Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, Ueda K, Sugimura T, Wakabayashi K. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008; 29: 8249.
  • 29
    Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 15978.
  • 30
    Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, Tosatti MP, Presta M. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol 2003; 162: 191326.
  • 31
    Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001; 19: 102934.
  • 32
    Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Brakenhielm E, Cao Y. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007; 117: 276677.
  • 33
    Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 13947.
  • 34
    Ruotsalainen T, Joensuu H, Mattson K, Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 14925.
  • 35
    Seymour L, Dajee D, Bezwoda WR. Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 1993; 26: 24752.
  • 36
    Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007; 14: 28594.
  • 37
    Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemostasis 2007; 97: 33642.
  • 38
    Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003: S4658.
  • 39
    Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehtab O, Guigo R, Gladyshev VN. Characterization of mammalian selenoproteomes. Science 2003; 300: 143943.